Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.62 |
| ▸ | PRKCA | P17252 | 2/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.62 |
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | CNR1 | P21554 | 1/20 | 0.59 |
| ▸ | CNR2 | P34972 | 1/20 | 0.59 |
| ▸ | TERT | O14746 | 3/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.58 |
| ▸ | PPARG | P37231 | 3/20 | 0.58 |
| ▸ | PPARD | Q03181 | 3/20 | 0.58 |
| ▸ | PPARA | Q07869 | 3/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.58 |
| ▸ | BLM | P54132 | 2/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9440104 | 1.00 | LMNA (0.62) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL17639936 | 1.00 | LMNA (0.62) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL9439767 | 1.00 | LMNA (0.62) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3656169 | 0.92 | PRKCA (0.58) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL1034384 | 0.92 | PRKCA (0.58) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL1034386 | 0.92 | PRKCA (0.58) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3658843 | 0.91 | LMNA (0.60) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3658837 | 0.91 | LMNA (0.60) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL3659878 | 0.91 | LMNA (0.60) | LMNAPRKCAPRKCEPRKCQPRKCD | |
| SCHEMBL6429415 | 0.90 | LMNA (0.79) | LMNAPRKCAPRKCEPRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2903987-B1 | PHOSPHOLIPID DRUG ANALOGS | UROGEN PHARMA LTD (IL) | 2017-09-20 | — | — | EP | disclosed |
| US-9540407-B2 | Phospholipid drug analogs | UROGEN PHARMA LTD (IL) | 2017-01-10 | — | — | US | disclosed |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2016-03-31 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9180183-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-10 | — | — | US | disclosed |
| US-9173936-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173936-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173935-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9173935-B2 | Phospholipid drug analogs | TELORMEDIX SA (CH) | 2015-11-03 | — | — | US | disclosed |
| US-9050319-B2 | Phospholipid drug analogs | TELORMEDIX, SA (CH) | 2015-06-09 | — | — | US | disclosed |
| US-20130273144-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130273144-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2013-10-17 | — | — | US | disclosed |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT (GB) | 2013-10-10 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | BIOPHARMA CREDIT PLC (GB) | 2012-01-12 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | TELORMEDIX SA (CH) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120003298-A1 | METHODS FOR INDUCING AN IMMUNE RESPONSE | CD4, IL4, CCR4 | LMNA 3863/4885PRKCA 4853/4885PRKCE 4866/4885 |
| US-20130267481-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | LMNA 786/4885PRKCA 4666/4885PRKCE 4592/4885 |
| US-20130273144-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | LMNA 786/4885PRKCA 4666/4885PRKCE 4592/4885 |
| US-20160090395-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | LMNA 786/4885PRKCA 4666/4885PRKCE 4592/4885 |
| US-20130266635-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | LMNA 786/4885PRKCA 4666/4885PRKCE 4592/4885 |
| US-20120009247-A1 | PHOSPHOLIPID DRUG ANALOGS | PHOSPHO1, PXMP4, SGMS1 | LMNA 786/4885PRKCA 4666/4885PRKCE 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.